Company / Operating Cash Flow
Vir Biotechnology, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$391.8M
FY2025
5-year range
-$778.8M / -$129.6M
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
#204 of 216
Health Care
What the data says
Among 216 Health Care companies, Vir Biotechnology, Inc. is in the bottom 6% for operating cash flow. Operating Cash Flow has fluctuated over the past 9 years, ranging from -$779M in FY2023 to -$66M in FY2017.
Based on SEC 10-K filings.
-$392M in FY2025.
Improved from -$779M to -$392M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 216This company -$391.8M Sector average $658.7M
▼
-159.5% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 12.2% year-over-year.
- Ranks #204 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$391.8M | +12.2% |
| FY2024 | -$446.4M | +42.7% |
| FY2023 | -$778.8M | -307.9% |
| FY2022 | -$190.9M | -47.3% |
| FY2021 | -$129.6M | +32.1% |
| FY2020 | -$190.9M | -47.3% |
| FY2019 | -$129.6M | -37.8% |
| FY2018 | -$94.1M | -41.8% |
| FY2017 | -$66.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026